Tot'Hema

Quick links to important sections

Tot'Hema

Method of action: Vitamins

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tot'Hema

Quick Facts

Property Description
Active Ingredients Ferrous Gluconate, Manganese Gluconate, Copper Gluconate, Cyanocobalamin
Form Oral Solution (in single-dose ampoules)
Pharmacological Class Antianaemic Preparations / Hematinics
General Purpose Corrects mineral/vitamin deficiencies that cause anemia
Origin Combination of synthetic mineral salts and vitamin

Tot'Hema: Classification and Definition of the Preparation

Tot'Hema is a pharmaceutical combination drug specifically designed as an antianaemic preparation or hematinic, primarily used to support the body’s processes for creating healthy red blood cells. Its therapeutic action is based on a synergistic formulation combining Ferrous Gluconate (an iron salt) with key accessory oligoelements, Manganese Gluconate and Copper Gluconate, alongside Cyanocobalamin (Vitamin B12), to optimize mineral replenishment. This multi-component approach distinguishes it from simpler, single-ingredient iron supplements.


Composition, Form, and General Purpose

The core active ingredients are these mineral salts and the B-vitamin, presented as an oral solution in single-dose ampoules, intended for the oral route of administration. The use of gluconate salts for the minerals is characterized by favorable bioavailability profiles. The inclusion of Cyanocobalamin is vital, as this compound is necessary for the proper maturation of red blood cells in the bone marrow.

The general purpose of this combination is to provide a comprehensive and highly bioavailable source of the micronutrients necessary to correct deficiencies, primarily iron deficiency, that impair blood cell function. By combining Iron with synergistic oligoelements and Vitamin B12, the preparation fundamentally supports hematopoiesis, which is the process of blood cell formation. Its action helps restore the body's capacity for effective oxygenation, which in turn alleviates the systemic symptoms often associated with deficiency, such as fatigue and generalized weakness.

What side effects are possible with Tot'Hema?

Possible Side Effects and Safety Information

The safety profile of this combination preparation, primarily associated with the oral administration of iron salts, is formally classified into several frequency and organ system categories by regulatory authorities.


Adverse Reactions by Classification

Adverse reactions are most frequently reported within the Gastrointestinal Disorders category. Regulatory documents classify the occurrence of side effects using standardized frequency bands:

Frequency Classification Examples of Reactions
Very Common Black stool discoloration (an expected physiological consequence)
Common Nausea, Vomiting, Constipation, Diarrhea, Abdominal pain/Stomach discomfort
Uncommon Tooth discoloration (generally related to administration)
Rare Hypersensitivity reactions (e.g., rash, pruritus)

Serious Safety Considerations

The most critical safety concern documented in regulatory labeling is the risk of Acute Iron Overdose Toxicity, which poses a severe, potentially fatal risk, particularly to the Pediatric Population. For this reason, official advisories emphasize stringent handling protocols for oral iron preparations. Anaphylactic Reaction is also documented as a rare but serious adverse event.


Population and Time-Related Safety

Official labels define safety constraints for specific groups. The preparation is contraindicated in individuals with documented iron accumulation diseases, such as Hemochromatosis, or those with pre-existing active peptic ulcers or other inflammatory bowel conditions. Furthermore, regulatory texts note that gastrointestinal adverse effects are often more frequent at the start of treatment and may diminish with continued use.

Overdose and Emergency Response

Tot'Hema Overdose and when to seek help

Accidental or intentional ingestion of excessive amounts of iron supplements, such as Tot'Hema, can lead to serious and potentially fatal poisoning, particularly in young children. Iron toxicity follows a multi-stage clinical course, beginning with gastrointestinal effects and potentially progressing to systemic organ damage.

Symptoms of Acute Iron Overdose

Symptoms typically develop within six hours of ingestion and can range from mild discomfort to severe systemic toxicity:

Early Symptoms (Initial 0-6 hours) Severe Systemic Symptoms (Later Stages)
Nausea and persistent vomiting (may be bloody) Severe hypotension (shock)
Diarrhea (may be bloody or black) Metabolic acidosis
Severe abdominal pain, lethargy, or drowsiness Liver failure (jaundice, coagulopathy)
Signs of gastrointestinal irritation/necrosis Coma and seizures

When to Seek Emergency Help

Acute iron poisoning is a medical emergency. You must immediately contact emergency services or go to the nearest hospital emergency department if you or a child have swallowed more than the prescribed dose, or if any of the above symptoms appear. Do not wait for symptoms to worsen.

Prompt treatment is critical. Management often involves supportive care, gastrointestinal decontamination, and in severe cases, chelation therapy with deferoxamine to remove excess iron from the bloodstream.

Therapeutic Uses of Tot'Hema

What Tot'Hema Treats: Main Uses and Benefits


The primary therapeutic role is applied across domains where additional symptomatic support is needed due to established deficiency states. This medication is generally used for the treatment of both established iron deficiency anaemia (IDA) and the precursor state of latent iron deficiency. It is applied across domains where additional symptomatic support is needed to address the condition marked by the deficiency of minerals required for healthy blood production, contributing to support for the functional stability of the body. Supplementation is relevant when dietary intake is insufficient or the body requires additional support.

The preparation is commonly used to help with symptoms related to systemic imbalance, particularly chronic fatigue, generalized weakness, and symptoms related to noticeable physiological strain. By addressing the deficit, the preparation supports the patient during episodes of physical discomfort and contributes to easing the overall symptom load that interferes with daily functioning.

“This treatment helps manage symptoms that interfere with daily comfort and supports general well-being during symptomatic phases.”

It is commonly applied as a prophylactic measure in high-risk groups, such as pregnant women and growing children, to prevent the onset of iron deficiency. The preparation is relevant for easing symptoms within therapeutic areas including: the management of IDA, the relief of chronic systemic fatigue, and preventative support in high-demand states.


Quick Fact: Relief for Fatigue Description
Primary Indication Iron deficiency anaemia (IDA) and latent deficiency
Symptom Focus Chronic fatigue, generalized weakness, reduced physical stamina
Scenario Prophylaxis during pregnancy and treatment in children
Patient Benefit Contributes to easing the overall symptom load and supports improved comfort.

Regulatory References

  1. NIH MedlinePlus overview of Iron Supplements

Eligibility and Restrictions for Use

Eligibility for Tot'Hema

Tot'Hema (ferrous gluconate, manganese gluconate, and copper gluconate) is an iron supplement specifically authorized for the treatment of iron deficiency anemia in adults, children, and infants (from one month of age). It is also used to prevent iron deficiency in pregnant women (typically from the fourth month), premature infants, and children when dietary intake is insufficient.


Contraindications and Restrictions

Use of this medicine is strictly prohibited (contraindicated) for individuals with an excess of iron in the body (iron overload) or a known hypersensitivity (allergy) to the active ingredients or excipients. It must not be taken for anemia not caused by iron deficiency, such as thalassemia or inflammatory anemia.

Use is not recommended for patients with rare hereditary diseases like fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency due to the sugar content. Caution and careful consideration are required for patients with existing gastrointestinal diseases (e.g., gastritis, inflammatory bowel disease) or liver dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tot'Hema is primarily defined by the Ferrous Gluconate component, which is a polyvalent iron cation. Official regulatory documents classify these as pharmacokinetic interactions resulting from chelation, where the iron forms complexes in the gastrointestinal tract, significantly reducing the absorption of co-administered substances.


Restrictions and Timing Requirements

Classification Interacting Product Category Regulatory Constraint
Non-Recommended Injectable Iron Salts Risk of systemic shock or syncope.
Timing Separation Oral Tetracyclines and Fluoroquinolones Must be separated by more than two hours to ensure adequate absorption.
Timing Separation Thyroid Hormones (e.g., Levothyroxine) Must be separated by at least four hours to prevent decreased hormone plasma concentration.
Timing Separation Levodopa, Carbidopa, Antacids, Bisphosphonates Requires separation by more than two hours to prevent reduced efficacy of these agents.

Food and Supplement Interactions

Specific dietary substances are officially documented to impair iron absorption. Consuming tea, coffee, phytic acids (in whole grains), calcium (in dairy), or certain proteins along with the preparation may significantly reduce the amount of iron absorbed into the body. To prevent this reduction in iron exposure, the regulatory advice is to separate the intake of these items from the medicine by more than two hours.

Mechanism of Action

How Tot'Hema Works

Tot'Hema's mechanism of action centers on the targeted delivery of essential micronutrients to support core metabolic pathways. The drug provides ferrous iron ( Fe^2+) gluconate, a salt form with demonstrated properties for mucosal transport, alongside manganese and copper. The initial step involves the dissolution of the ferrous salt and subsequent translocation of the divalent ions across specific mucosal transporters in the gastrointestinal tract, facilitating their entry into the plasma pool.

Following mineral transport, the systemic availability of iron serves as the crucial substrate for heme synthesis, the rate-limiting step in the erythropoietic cascade within the bone marrow. Copper acts as an essential cofactor for ferroxidases, which are required to mobilize iron for transport and subsequent incorporation into the protoporphyrin ring. This combined activity directly augments the pathway, resulting in the synthesis and maturation of erythrocytes.

The resultant increase in hemoglobin concentration and red blood cell count facilitates the enhanced transport and delivery of oxygen to peripheral tissues, constituting the final system-level physiological modulation of the drug's mechanism.

Dosage and Administration Information

The administration of Tot'Hema is limited to the oral route; the solution must not, under any circumstance, be administered intravenously. The preparation is delivered as a liquid in a single-dose ampoule, requiring mandatory dilution before consumption. The contents of the ampoule must first be shaken and then mixed completely into a glass of water or other non-alcoholic liquid.

Dosing for the curative treatment of established iron deficiency anemia in adults typically ranges from 100 to 200 mg of elemental iron daily, which corresponds to two to four ampoules. This daily dose may be taken at once or divided into smaller amounts to manage gastrointestinal tolerance. For prophylactic use in pregnant women, the typical daily dose is 50 mg of elemental iron, beginning from the second trimester. Pediatric dosing for curative use is standardized at 5 to 10 mg of elemental iron per kilogram of body weight per day.

The solution is generally intended to be taken before meals for optimal absorption; however, the timing may be adjusted to immediately after a meal if necessary. Proper use also requires adherence to a defined duration pattern: while initial treatment may vary, the course generally lasts 3 to 6 months and must be continued for approximately three additional months after the patient's blood parameters return to normal. Furthermore, a procedural condition for proper use involves separating the administration of Tot'Hema from certain dietary items, such as tea, and specific medications by an interval of at least two hours to prevent absorption interference.

Recent Clinical Evidence

Evidence for the Treatment of Iron Deficiency Anemia (IDA)

Research was studied for use in clinical situations marked by iron deficiency anemia (IDA) or its precursor state, latent iron deficiency. Studies available include systematic reviews and controlled investigations that examined the four-component formula. The research has explored outcomes related to measured physiological variables, with studies measuring changes in key blood markers like Hemoglobin and Ferritin. Findings describe patterns observed, including shifts in iron stores following the defined observation period. However, evidence for the specific combination often relies on open-label or non-randomized studies, and comparative evidence against standard iron monotherapy in large adult populations is lacking.


Evidence for Prophylaxis (Prevention) in High-Risk Groups

Evidence supporting the preventative use of oral iron preparations in high-risk groups, such as during pregnancy or in young children, primarily comes from comprehensive systematic reviews and meta-analyses of oral iron supplementation in general. These studies were designed to monitor levels of iron status biomarkers, examining outcomes related to the incidence of iron deficiency. The evidence base is supported by high-quality meta-analyses. Research currently provides limited information to isolate the specific preventative contribution of the Manganese, Copper, and Cyanocobalamin components in the combination drug when used for prophylaxis.


Long-Term Studies and Follow-Up

Studies generally explore the short-term therapeutic response to iron supplementation. The initial therapeutic response, where researchers monitored changes in blood markers, was observed over defined time intervals, such as 4 to 6 weeks. While the full correction of iron stores may require several months of observation, long-term effects are not fully established. There is limited information for outcomes related to the durability of the initial response and sustained maintenance of corrected iron levels over many years.


What Remains Uncertain and Research Gaps

Research limitation frames are noted in the scientific literature. Evidence quality varies across studies specific to the four-component combination, and comparative evidence is lacking for the specific combination drug against standard iron monotherapy in large, diverse adult populations. Therefore, the data for certain groups remain insufficient, and the long-term effects are not fully established regarding the sustained outcomes. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Tot'Hema (FAQ)


Q: How quickly should I expect to see an effect from Tot'Hema?

Studies and official information indicate that the initial therapeutic response is often assessed by physicians through changes in key blood markers, such as hemoglobin or ferritin. This response is frequently observed by researchers over defined periods, sometimes noted as four to six weeks. The full restoration of the body's iron stores often requires a longer duration of observation and treatment.


Q: Can Tot'Hema be taken with vitamin C supplements?

Some authoritative health sources suggest that Vitamin C (Ascorbic Acid) may promote the absorption of oral iron supplements, including this preparation. Regulatory information on oral iron usually highlights the need to separate intake from substances that inhibit absorption, but generally does not restrict the use of absorption enhancers.


Q: Does Tot'Hema interact with medications for thyroid issues?

Yes, official regulatory documents specify an interaction with thyroid hormones, such as levothyroxine. Regulatory documents specify that the administration of this preparation and thyroid hormones should be separated by at least four hours to help prevent a decrease in the hormone's concentration in the bloodstream.


Q: Is it necessary to have certain blood tests before starting Tot'Hema?

The medicine is indicated for use following the confirmation of iron deficiency. Additionally, regulatory texts state that its use is prohibited if there is an existing excess of iron in the body. Therefore, professional medical guidance typically involves blood tests to confirm eligibility and rule out conditions of iron overload.


Q: What is meant by the 'complex' form of iron in Tot'Hema?

The active iron ingredient is ferrous gluconate, which is defined as a specific salt form of ferrous iron ( Fe^2+). Official pharmacological properties describe this salt form as having favorable characteristics for transport across the lining of the gut, which helps facilitate its absorption into the body.


Q: Can people with certain digestive conditions still use Tot'Hema?

Official information states that the medicine is strictly prohibited (contraindicated) for patients who have active peptic ulcers. Furthermore, caution and careful consideration are required for individuals with other existing gastrointestinal diseases such as gastritis or inflammatory bowel disease.


Q: Is it true that Tot'Hema should be diluted before taking it?

Yes, the official prescribing information strongly emphasizes that the contents of the ampoule require mandatory dilution. The solution must be completely mixed into a glass of water or any other non-alcoholic liquid prior to consumption.


Q: Why is there a specific instruction about the time between taking Tot'Hema and other medicines?

The required timing separation is due to the iron component being a polyvalent cation. It can form molecular complexes (known as chelation) with co-administered substances in the stomach, which significantly reduces the absorption and effectiveness of both this preparation and the other medicine.


Q: What do official sources say about taking Tot'Hema on an empty stomach?

Official information notes that the solution is generally intended to be taken before meals for optimal absorption. However, the timing may be adjusted to immediately after a meal if necessary to help improve gastrointestinal tolerance.


Q: What happens if I miss a dose of Tot'Hema?

General authoritative information for iron supplements often suggests taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, skipping the missed dose and continuing with the regular schedule is commonly suggested. Taking a double dose is generally advised against.


Q: Is it possible to take too much Tot'Hema?

Yes, accidental high intake can lead to Acute Iron Overdose Toxicity, which poses a severe, potentially fatal risk, especially to the pediatric population. Official advisories emphasize stringent handling protocols to help prevent this critical risk.


Q: Does Tot'Hema affect blood sugar levels?

Official documentation lists sugar compounds, specifically glucose and sucrose, as inactive ingredients (excipients) in the preparation. Due to this sugar content, the medicine is noted as being unsuitable for patients with rare hereditary diseases like fructose intolerance or glucose malabsorption.


Q: What are the general expectations for recovery after using Tot'Hema?

The drug’s purpose is to correct mineral deficiencies that impair blood cell formation. Its mechanism is designed to support the body’s oxygen transport processes, which is intended to address systemic symptoms, such as fatigue and generalized weakness, associated with the iron deficiency.


Q: Does alcohol consumption affect how Tot'Hema works?

Official administration instructions specify that the preparation must be diluted in a non-alcoholic liquid for consumption. While a direct interaction warning with alcohol is not typically listed, the administration instructions indicate its use should be separated from alcohol.


Q: Is there any information about Tot'Hema use in elderly patients?

Official safety warnings specifically note that elderly patients, and those who have difficulties swallowing, are at increased risk. This is due to the possibility of accidental aspiration of the oral solution, which is a documented risk for this population.


Q: Can Tot'Hema cause allergic reactions?

Yes, a known hypersensitivity (allergy) to the active ingredients is listed as a contraindication for use in regulatory documents. Documented adverse reactions, though rare, include hypersensitivity events such as rash and pruritus, and anaphylactic reaction is noted as a serious but rare event.


Q: Is it important to take Tot'Hema at the same time every day?

General authoritative information for iron supplements often suggests taking the medicine at approximately the same time each day. This practice is commonly suggested to help establish a regular routine and support adherence to the treatment schedule.


Q: Are there any long-term side effects noted for Tot'Hema?

Official studies primarily focus on the short-term therapeutic response. The long-term effects regarding sustained outcomes are not fully established in the literature. Regulatory texts also note that the sugar content (glucose and sucrose) may potentially be harmful to the teeth in cases of very prolonged use.


Q: Does Tot'Hema help with general fatigue?

The medicine is officially intended to correct mineral deficiencies that cause anemia. Its mechanism is designed to support the body's oxygen transport processes, which is intended to address systemic symptoms, such as fatigue, associated with the iron deficiency.


How should Tot'Hema be stored and disposed of?

Storage and Disposal of Tot'Hema Oral Solution

The storage and disposal of Tot'Hema must strictly adhere to the conditions outlined in regulatory labeling to maintain product stability and ensure environmental safety.


Official Storage Requirements

Condition Requirement
Temperature Do not store above 30 C (some regulations specify 25 C).
Child Safety Must be kept out of the sight and reach of children.
Shelf Life Do not use after the expiry date; the unopened product shelf life is 2 years.

Official Disposal Rules

The medicine should not be discarded via wastewater or household waste to protect the environment. Unused or expired Tot'Hema must be disposed of according to instructions provided by a pharmacist, adhering to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tot'Hema found in:

A-Z Index: